Trial Profile
A phase I trial of docetaxel [Taxotere] and PTK787 [vatalanib] in metastatic breast cancer patients and recurrent or refractory gynecological cancer patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2017
Price :
$35
*
At a glance
- Drugs Vatalanib (Primary) ; Docetaxel
- Indications Advanced breast cancer; Gynaecological cancer
- Focus Adverse reactions
- 20 Dec 2007 Status change from recruiting to in progress.
- 13 Jan 2006 New trial record.